The pharmaceutical landscape has witnessed a groundbreaking shift with the emergence of copyright and Wegovy, two medications formulated to address the complex issue of obesity. These innovative treatments leverage the potential of glucagon-like peptide-1 (GLP-1) receptor agonists, a class of drugs known to modulate appetite and blood sugar levels.